More than 476,000 new cases of Lyme disease are diagnosed each year in the United States U.S. Department of Health and Human Services, 2022 — making it, by a wide margin, the most common tick-borne disease in the country. Even that number likely undercounts the true burden: the CDC previously estimated approximately 300,000 annual cases based on a roughly 10:1 underreporting ratio American Society for Microbiology, 2019, and the updated figure reflects insurance claims analysis rather than passive surveillance. An estimated three-quarters of all cases are acquired from ticks picked up during activities around the home Connecticut Agricultural Experiment Station / CDC, 2007. Tick-borne diseases as a whole represent more than 75% of all reported vector-borne infections in the United States U.S. Department of Health and Human Services, 2022, and Lyme disease dominates that picture.

The pathogen and its vectors

Lyme disease is caused by the spirochete Borrelia burgdorferi (Lyme disease bacterium), transmitted primarily by Ixodes scapularis (black-legged tick / deer tick) in the eastern and central United States and by Ixodes pacificus (western black-legged tick) in the West American Society for Microbiology, 2019, Connecticut Agricultural Experiment Station / CDC, 2007. The white-footed mouse is the principal reservoir for B. burgdorferi, Babesia microti (Babesia parasite), and Anaplasma phagocytophilum (anaplasmosis bacterium), making it the single most important wildlife host in the Lyme disease transmission cycle Connecticut Agricultural Experiment Station / CDC, 2007.

Between 1996 and 2016, the number of US counties with established populations of I. scapularis doubled to 44.7% American Society for Microbiology, 2019. Climate change is expanding tick ranges to higher latitudes and altitudes, with predictive models forecasting further increases in Lyme disease incidence ScienceDirect / Elsevier, 2025.

Transmission of B. burgdorferi requires 36 to 72 hours of tick attachment American Society for Microbiology, 2019, MDPI (Vaccines), 2024 — a longer window than many other tick-borne pathogens, which is why prompt tick removal remains a cornerstone of prevention. Twelve states accounted for 95% of reported US Lyme disease cases as of 2002 data Connecticut Agricultural Experiment Station / CDC, 2007, and greatest incidence occurs in children under 14 and adults over 40 Connecticut Agricultural Experiment Station / CDC, 2007.

The bull's-eye rash and early disease

The hallmark of early Lyme disease is erythema migrans (EM) — the expanding rash that occurs in approximately 70–80% of patients, appearing 3 to 30 days after a tick bite (typically 7–14 days) American Society for Microbiology, 2019, Connecticut Agricultural Experiment Station / CDC, 2007, Centers for Disease Control and Prevention, 2022. The EM rash should not be confused with the transient hypersensitivity reaction to a tick bite (less than 5 cm) that disappears within 24–48 hours Connecticut Agricultural Experiment Station / CDC, 2007.

For erythema migrans, clinical diagnosis without laboratory testing is recommended when the rash is present in a patient from a high-incidence area — serologic testing is not needed and may be negative in early disease IDSA / AAN / ACR, 2020.

When it spreads: disseminated and late-stage disease

"Untreated or unnoticed early Lyme disease will progress to disseminated disease for about 60% of patients, with diverse clinical manifestations." Centers for Disease Control and Prevention, 2022

Early disseminated disease — appearing in the first weeks to months of untreated infection — includes neurologic symptoms in 10–15% of untreated patients Connecticut Agricultural Experiment Station / CDC, 2007 and Lyme carditis (various degrees of intermittent atrioventricular heart block) in 4–10% of untreated patients, which may require hospitalization Connecticut Agricultural Experiment Station / CDC, 2007. Approximately 1% of CDC-confirmed cases had second- or third-degree heart block American Society for Microbiology, 2019.

Late-stage Lyme disease manifests primarily as arthritis: approximately 50–60% of untreated patients develop arthritis, and about 10% of those may have chronic joint inflammation Connecticut Agricultural Experiment Station / CDC, 2007. Detection and treatment early after infection appears to have reduced the incidence of later arthritic and neurologic manifestations Connecticut Agricultural Experiment Station / CDC, 2007.

Why the standard test misses early cases

The standard two-tier testing approach for Lyme disease — an initial EIA (enzyme immunoassay) followed by Western blot if positive — has well-documented limitations, particularly in early disease. Modified two-tier testing (MTTT), using two EIAs run concurrently instead of EIA followed by Western blot, was recently FDA-cleared and improves sensitivity for early infections while being less subjective, less labor-intensive, and faster than standard two-tier testing American Society for Microbiology, 2019.

Research-phase metabolomic testing for Lyme disease has shown 88% sensitivity and 95% specificity American Society for Microbiology, 2019, though this remains experimental. Diagnosis and disease surveillance are the principal areas of focus in published tick-borne disease literature, while treatment research is underrepresented — covered in only 4% of published articles U.S. Department of Health and Human Services, 2024.

"Prevention products and diagnostic technologies are badly needed, yet there is no clear path to bring them to market, and little has been done to remove existing barriers." U.S. Department of Health and Human Services, 2022

Treatment: what the guidelines say

The 2020 IDSA/AAN/ACR clinical practice guideline — the first joint guideline from three major medical societies, using GRADE methodology — provides the current standard of care IDSA / AAN / ACR, 2020. For erythema migrans, doxycycline 100 mg twice daily for 10–14 days is the treatment of choice in adults, with amoxicillin 500 mg three times daily for 14 days and cefuroxime 500 mg twice daily for 14 days as alternatives Centers for Disease Control and Prevention, 2022, IDSA / AAN / ACR, 2020.

For prophylaxis after a tick bite, the guideline recommends a single dose of doxycycline 200 mg when: the bite occurred in a high-incidence area, the tick is identified as a blacklegged tick, estimated attachment time is 36 hours or more, and prophylaxis can begin within 72 hours of tick removal IDSA / AAN / ACR, 2020.

"Lyme disease is probably both over-diagnosed and under-diagnosed with groups of patients, some of whom without Lyme disease convinced they have it while other patients with the disease being told they do not have it." Connecticut Agricultural Experiment Station / CDC, 2007

Coinfection with Babesia microti or Anaplasma phagocytophilum should be considered in patients whose initial symptoms are more severe than commonly observed with Lyme disease alone, especially with high-grade fever persisting more than 48 hours despite appropriate antibiotic therapy Centers for Disease Control and Prevention, 2022.

The treatment guidelines controversy

The treatment of Lyme disease remains contested. The IDSA guidelines represent the mainstream clinical consensus, but the 2022 HHS Tick-Borne Disease Working Group Report to Congress — the third and final congressionally mandated report under the 21st Century Cures Act — documented ongoing patient barriers and treatment access gaps U.S. Department of Health and Human Services, 2022.

"Multiple subcommittees highlighted that federally organized programs have been the best means for making progress in their topic areas—underscoring the breadth and diversity of the diseases caused by ticks." U.S. Department of Health and Human Services, 2022

"Several subcommittees cited increased government intervention in the development of diagnostics and treatment protocols as detrimental to transforming the tick-borne disease landscape. The subcommittee members believed that progress has been impeded by a heavy regulatory burden and low likelihood of profitability, which discourage the private-sector investments needed to catalyze the entry of new products into the market." U.S. Department of Health and Human Services, 2022

"Treatment of tick-borne diseases and associated illnesses, previously identified as a major gap, remains covered in only 4% of the articles." U.S. Department of Health and Human Services, 2024

Post-Treatment Lyme Disease Syndrome

"Post-treatment Lyme disease syndrome (PTLDS), which may also be referred to incorrectly as 'chronic Lyme disease,' is defined by the Infectious Diseases Society of America (IDSA) as the presence of fatigue, pain, and/or cognitive complaints with the functional impact that persists for more than six months after completing treatment for Lyme disease." Cureus / PMC, 2024

"These symptoms occur in 10%-20% of patients previously diagnosed with LD caused by the bacteria Borrelia burgdorferi and appropriately treated with a course of antibiotics." Cureus / PMC, 2024

The Johns Hopkins Lyme Disease Research Center conducted the largest US prospective controlled study of PTLDS outcomes, following 234 participants with prior early Lyme disease and 49 controls. The findings confirmed what patients have long reported: 13.7% of ideally-diagnosed, promptly-treated early Lyme disease patients met criteria for PTLD, compared to 4.1% of controls — a 5.28-fold increased likelihood (p=0.042) International Journal of Infectious Diseases / Johns Hopkins Lyme Disease Research Center, 2022. Participants with prior Lyme disease had 8 to 15 times higher odds of reporting moderate or severe fatigue and muscle pain compared to controls International Journal of Infectious Diseases / Johns Hopkins Lyme Disease Research Center, 2022.

This study is significant because it demonstrates PTLDS in the best-case clinical scenario — patients diagnosed early and treated promptly with appropriate antibiotics. If even "ideal" patients develop PTLDS at nearly 14%, the rate in delayed-diagnosis or undertreated patients is likely higher International Journal of Infectious Diseases / Johns Hopkins Lyme Disease Research Center, 2022. Risk factors include female sex, prior traumatic life events, delayed diagnosis, incomplete treatment, and preexisting comorbidities International Journal of Infectious Diseases / Johns Hopkins Lyme Disease Research Center, 2022, Cureus / PMC, 2024.

Five mechanisms have been proposed to explain PTLDS: permanent tissue damage and inflammation from the spirochete infection, immune system dysfunction, autoimmune response triggered by infection, co-infection with other tick-borne pathogens, and persistent infection refractory to antibiotic treatment Cureus / PMC, 2024. Borrelia burgdorferi has sophisticated immune evasion capabilities — it downregulates immunogenic surface proteins, manipulates host proteins to shield from complement-mediated lysis, and inhibits antibody-mediated killing — mechanisms that may contribute to persistent tissue damage even after bacterial clearance Cureus / PMC, 2024. No quantifiable biomarker exists for PTLDS as of 2024 Cureus / PMC, 2024. PTLDS shares pathophysiological features with long COVID and chronic fatigue syndrome, suggesting these post-infectious syndromes may share common immune dysregulation mechanisms Cureus / PMC, 2024.

The vaccine that was and the one that might be

"The withdrawal of the human Lyme disease vaccine (LYMErix™) in 2002 has essentially brought the control of the disease back to managing tick bites and methods to suppress the local tick population or prevalence of pathogen infection in the ticks." Connecticut Agricultural Experiment Station / CDC, 2007

LYMErix, an OspA-based vaccine, was the only human Lyme disease vaccine ever marketed. Its withdrawal in 2002 — amid declining sales and litigation alleging adverse effects — left no human vaccine available Connecticut Agricultural Experiment Station / CDC, 2007, Journal of Medical Entomology / PMC, 2021. Nearly two decades later, only one candidate has reached advanced clinical trials: VLA15 (Valneva/Pfizer), which had progressed to Phase 2 clinical trials as of the Eisen and Stafford review Journal of Medical Entomology / PMC, 2021.

Anti-tick vaccines targeting tick proteins essential for feeding — cement proteins, saliva components — offer a fundamentally different approach: the potential to block transmission of multiple pathogens simultaneously rather than targeting a single pathogen MDPI (Vaccines), 2024. Gavac, targeting the Bm86 protein of Rhipicephalus microplus, is the only commercially available anti-tick vaccine, used in livestock but not yet adapted for human use or other tick species MDPI (Vaccines), 2024.

"Despite significant investment at all levels to respond to tick-borne diseases and associated illnesses, the combined response remains inadequate." U.S. Department of Health and Human Services, 2022

The scale of the systemic gap

Nine tick species transmit at least 18 disease-causing bacteria, viruses, and parasites in the United States, and nearly half of these pathogens were discovered in just the past two decades U.S. Department of Health and Human Services, 2022. Tick-borne disease research largely focuses on Lyme disease, with fewer publications examining other conditions — creating significant knowledge gaps for non-Lyme diseases U.S. Department of Health and Human Services, 2022. Yet even for Lyme disease, the dominant research subject, treatment research remains critically underrepresented U.S. Department of Health and Human Services, 2024, and significant gaps exist in research involving disadvantaged groups: lower socioeconomic status, regional and rural populations, racial and ethnic minorities, and high-risk outdoor workers U.S. Department of Health and Human Services, 2022.

"A new major theme identified by multiple subcommittees is the prioritization of health equity for sufferers of tick-borne diseases and associated illnesses." U.S. Department of Health and Human Services, 2022

Sources

Compiler Notes

  • The user-provided source list included 2023_MDPI_TickBorneDiseaseVaccines_Review and 2024_ScienceDirect_TBD_ComprehensiveReview — these do not exist in the index under those filenames. The closest matches are 2024_MDPI_AntiTickVaccines_ComprehensiveReview and 2025_ScienceDirect_TBD_Epidemiology_Pathogenesis_Prevention, which were used instead.
  • The user-provided filename 2019_JHU_PTLDS_ProspectiveCohort_Aucott corresponds to 2022_IntJInfectDis_PTLDS_ProspectiveCohort_JohnsHopkins_Aucott in the index.
  • The IDSA/ILADS treatment guidelines controversy is a significant topic in the vault's taxonomy (idsa-ilads-lyme-guidelines-controversy) but no dedicated ILADS source is indexed. The article covers the controversy through the TBDWG report's documentation of barriers and disagreements rather than presenting both guideline positions side by side. This is a potential source gap.
  • Specific VLA15 Phase 3 trial status is not documented in the index — the most recent reference (Eisen 2021) places VLA15 at Phase 2. Current trial status is a claim not in the index.
  • The 476,000 annual case estimate (HHS 2022) supersedes the 300,000 estimate (ASM 2019) — both are cited with temporal context.